T. Ahmad

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

Tim Eisen, T. Ahmad, Keith T. Flaherty et al. · British Journal of Cancer · 2006 · 636 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase I trial of BAY 43–9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients

Tim Eisen, T. Ahmad, M. Gore et al. · Journal of Clinical Oncology · 2005 · 50 citations

Medicine, Oncology, Pharmacology +17

BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience

T. Ahmad, Richard Marais, L Pyle et al. · Journal of Clinical Oncology · 2004 · 48 citations

Medicine, Oncology, Surgery +8

A Novel Point Mutation in P450c17 (CYP17) Causing Combined 17α-Hydroxylase/17,20-Lyase Deficiency

Antonia Brooke, Norman Taylor, J. H. Shepherd et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 47 citations · Full text

Life Sciences, Endocrinology, Genetics +17

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

Tim Eisen, Richard Marais, Annette Affolter et al. · British Journal of Cancer · 2011 · 43 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13